ACT jumps on encouraging data for stem cell vision treatment
This article was originally published in Scrip
Executive Summary
Although the data published this week about Advanced Cell Technology's human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cell treatment involved only two patients with vision disorders in a Phase I/II trial, investors' eyes focused on the potential meaning of the positive results to the company's future, with shares of the tiny US biotech rising as much as 27% on 23 January.